The impact of adulthood booster dose of Hepatitis B vaccine on antibody response in students

The impact of adulthood booster dose of Hepatitis B vaccine on antibody response in medical and nursing students of Qazvin University of Medical Sciences: a before-after study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201510142276N3

Enrollment

120

Registered

2015-11-22

Start date

2015-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B. Chronic (viral) hepatitis B

Interventions

Single dose intramuscular injection of 20 microgram of recombinant hepatitis B vaccine (Euvax B, LG corporations, South Korea).

Prevention

Single dose intramuscular injection of 20 microgram of recombinant hepatitis B vaccine (Euvax B, LG corporations, South Korea)

Eligibility

Sex/Gender

All

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: medical or nursing student before entering the clinical wards. Exclusion criteria: students with chronic hepatitis B; students with previous history of booster vaccination

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anti HBS antibody titer. Timepoint: One month after vaccination. Method of measurement: Serology (ELISA).	—

Secondary

Measure	Time frame
Vaccination side effects. Timepoint: During a month period after vaccination. Method of measurement: Participants' report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Jafari zavieh kord

Qazvin University of Medical Sciences

drjafari587@gmail.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026